Evidence map›Paper›PMID 30075336›Full record

ReviewProgress in retinal and eye research2018

Sigma 1 receptor: A novel therapeutic target in retinal disease.

Sylvia B Smith, Jing Wang, Xuezhi Cui, Barbara A Mysona, Jing Zhao, Kathryn E Bollinger

Open access · greenAbstract readReview
In one paragraph

Review in Progress in retinal and eye research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Sigma Receptors: Novel Regulators of Iron/Heme Homeostasis and Ferroptosis.International journal of molecular sciences · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. SIGMAR1 Confers Innate Resilience against Neurodegeneration.International journal of molecular sciences · 2023
    Review
  19. Review
  20. Sphingoid Bases Regulate the Sigma-1 Receptor-Sphingosine andInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sylvia B SmithDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, USA; The James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, USA; Department of Ophthalmology, Medical College of Georgia at Augusta University 30912, Augusta, GA, USA. Electronic address: sbsmith@augusta.edu.
Jing WangDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, USA; The James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, USA.
Xuezhi CuiDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, USA; The James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, USA.
Barbara A MysonaDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, USA; The James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, USA.
Jing ZhaoThe James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, USA; Department of Ophthalmology, Medical College of Georgia at Augusta University 30912, Augusta, GA, USA.
Kathryn E BollingerDepartment of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, USA; The James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, USA; Department of Ophthalmology, Medical College of Georgia at Augusta University 30912, Augusta, GA, USA.
Augusta University · US

Funding

The Mechanism of Sigma 1 Receptor Mediated Neuroprotection in GlaucomaR01EY027406 · NEI · AUGUSTA UNIVERSITY · PI Kathryn Bollinger · 2018 to 2026
$3.2M
Diabetic retinopathy: sigma receptor 1 (??R1) as a novel therapeutic target.R01EY014560 · NEI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI SMITH, SYLVIA B. · 2004 to 2013
$2.7M
Sigma 1 Receptor: a novel therapeutic target for retinal degenerationR01EY028103 · NEI · AUGUSTA UNIVERSITY · PI SMITH, SYLVIA B. · 2017 to 2019
$1.2M
Molecular Mechanisms of Sigma Receptor 1-Mediated NeuroprotectionK08EY021758 · NEI · AUGUSTA UNIVERSITY · PI BOLLINGER, KATHRYN · 2011 to 2015
$1.1M
NEI NIH HHS K08 EY021758NEI NIH HHS R01 EY014560NEI NIH HHS R01 EY027406NEI NIH HHS R01 EY028103
6 · The paper itself

Abstract

Retinal degenerative diseases are major causes of untreatable blindness worldwide and efficacious treatments for these diseases are sorely needed. A novel target for treatment of retinal disease is the transmembrane protein Sigma 1 Receptor (Sig1R). This enigmatic protein is an evolutionary isolate with no known homology to any other protein. Sig1R was originally thought to be an opioid receptor. That notion has been dispelled and more recent pharmacological and molecular studies suggest that it is a pluripotent modulator with a number of biological functions, many of which are relevant to retinal disease. This review provides an overview of the discovery of Sig1R and early pharmacologic studies that led to the cloning of the Sig1R gene and eventual elucidation of its crystal structure. Studies of Sig1R in the eye were not reported until the late 1990s, but since that time there has been increasing interest in the potential role of Sig1R as a target for retinal disease. Studies have focused on elucidating the mechanism(s) of Sig1R function in retina including calcium regulation, modulation of oxidative stress, ion channel regulation and molecular chaperone activity. Mechanistic studies have been performed in isolated retinal cells, such as Müller glial cells, microglial cells, optic nerve head astrocytes and retinal ganglion cells as well as in the intact retina. Several compelling studies have provided evidence of powerful in vivo neuroprotective effects against ganglion cell loss as well as photoreceptor cell loss. Also described are studies that have examined retinal structure/function in various models of retinal disease in which Sig1R is absent and reveal that these phenotypes are accelerated compared to retinas of animals that express Sig1R. The collective evidence from analysis of studies over the past 20 years is that Sig1R plays a key role in modulating retinal cellular stress and that it holds great promise as a target in retinal neurodegenerative disease.

Indexed as

Retinal DegenerationAnimalsHumansIon ChannelsMolecular ChaperonesMolecular Targeted TherapyNeuroprotectionNeuroprotective AgentsOxidative StressReceptors, sigmaSigma-1 ReceptorIon ChannelsMolecular ChaperonesNeuroprotective AgentsReceptors, sigmaSigma-1 Receptor

Identifiers

PMID30075336
PMCPMC6557374
OpenAlexW2886919003

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.